Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,195.77 19.80 0.62%
FTSE 100 6,718.09 43.35 0.65%
DAX 9,586.94 42.75 0.45%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

ALR Technologies Announces Development Partnership Agreement With Insulin Algorithms; Successful Integration of the Two


ALR Technologies Announces Development Partnership Agreement With Insulin Algorithms; Successful Integration of the Two Technology Platforms Could Lead to Near-Instantaneous Insulin Dosage Consultation and Adjustment

RICHMOND, VA -- (Marketwired) -- 11/05/13 -- ALR Technologies (OTCBB: ALRT) and Insulin Algorithms (InsulinAlgo) announced a technology partnership that would integrate Insulin Algorithm's insulin dosage adjustment software with ALRT's Health-e-Connect remote monitoring platform. An integration of the two technology platforms would create a revolutionary system that would allow patients to remotely upload their blood glucose data to the ALRT platform and then, within seconds, the patient's physician could be provided with an insulin dosage recommendation electronically when the patient's blood glucose data and patient profile were run through the Insulin Algorithm software. Proper dosing of insulin is one of the most important and challenging tasks in diabetes care and an effective system to dose insulin would reduce adverse events, improve outcomes and reduce the costs of care for patients living with diabetes.

ALRT's platform has received FDA 510(k) clearance but any commercial use of Insulin Algorithms' software will require additional U.S. Food and Drug Administration regulatory clearance. Under the agreement, ALRT will have access to the InsulinAlgo software to begin the integration process while InsulinAlgo's FDA clearance is pending. Once integrated and tested, and after final FDA clearance, the ALRT-InsulinAlgo system will be made available to the commercial marketplace both in the U.S. and internationally.

Insulin Algorithm's Founder and Chief Medical Officer, Dr. Mayer B. Davidson, said: "We are very excited about our partnership with ALRT. I have spent a career studying how to properly dose insulin and our algorithms embody that experience. This partnership with ALRT represents the potential to offer our expertise to many providers quickly and electronically, without the inconvenience of paper logbooks and unnecessary additional physician visits. We hope to serve as an experienced resource for those physicians who are on the front line of diabetes care."

ALRT's CEO Sidney Chan said: "We are honored to partner with Insulin Algorithms as its founder is one of the world's most renowned experts on the proper use of insulin. As the global pandemic has spread from the developed world to the emerging economies, we believe there is an urgent need to provide physicians and patients with the benefit of the very best thinking about proper insulin dosing. Our partnership has the potential to bring this knowledge as quickly and efficiently as a text message. We believe there is a worldwide market for this tool."

About Insulin Algorithms

Based on Dr. Mayer B. Davidson's 35 years of diabetes research, Insulin Algorithms has created software that will make specific insulin dosage adjustment recommendations based on the patient's current physical characteristics, insulin regimen, and the hundreds of individual readings they have every month. Dr. Davidson is Professor of Medicine at both the David Geffen School of Medicine at UCLA and Charles R. Drew University. Dr. Davidson was President of the American Diabetes Association in 1997-1998. A renowned researcher and speaker on type 2 diabetes and insulin resistance, Dr. Davidson has presented hundreds of lectures nationally and internationally. He has served on the Editorial Boards of Diabetes Care, Diabetes Spectrum, Clinical Diabetes, Diabetes Reports, Today in Medicine, Geriatrics and the Journal of Clinical Endocrinology and Metabolism and was a Consulting Editor of Hippocrates and an Associate Editor of Endo Trends. He currently serves on the Editorial Board of Diabetes Research & Clinical Practice. Further, Dr. Davidson was the Founding Editor of Current Diabetes Reports and was the Editor-in-Chief of Diabetes Care from 2002 through 2006, the leading clinical journal for the diabetes community. Dr. Davidson's contributions to the medical literature include 3 books on diabetes care, 168 scientific papers, 31 book chapters, 59 reviews and 54 editorials and invited articles. More information about Insulin Algorithms, Inc. can be found at www.insulinalgorithms.com.

About ALR Technologies Inc.

ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their HEDIS goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.

This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange

Contact: Bill Smith bill.smith@alrt.com 203.762.1073

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement